MUC20 (Mucin 20) is a member of the mucin family, a group of high-molecular-weight glycoproteins characterized by extensive glycosylation and roles in cell adhesion, lubrication, and signaling. Unlike classical secreted or transmembrane mucins, MUC20 is a secreted protein primarily expressed in epithelial and immune cells. It contains a conserved N-terminal domain and a C-terminal hydrophobic region, though its structural and functional properties remain less characterized compared to other mucins. Research suggests MUC20 interacts with the Met receptor tyrosine kinase, modulating hepatocyte growth factor (HGF)-mediated signaling pathways involved in cell proliferation, migration, and tissue repair. Dysregulation of MUC20 has been implicated in pathological conditions, including cancers (e.g., renal, gastric, and colorectal), chronic kidney disease, and inflammatory disorders. Its overexpression in certain tumors correlates with advanced stages and poor prognosis, potentially serving as a biomarker.
Antibodies targeting MUC20 are essential tools for studying its expression, localization, and mechanistic roles. They enable detection via techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding in both basic research and clinical diagnostics. Commercial MUC20 antibodies are typically raised against specific epitopes, such as recombinant protein fragments, and validated for cross-reactivity in human and model organisms. Challenges include ensuring specificity due to shared epitopes within the mucin family and variability in glycosylation patterns. Ongoing efforts focus on developing reliable antibodies to explore MUC20’s therapeutic potential, such as targeting its interaction with Met or its immune-modulatory functions. Understanding MUC20’s biology through antibody-based approaches may unlock insights into disease mechanisms and treatment strategies.